

REPLY TO THE RESPECTED REVIEWER'S COMMENTS

- 1) The title correctly indicates the nature of the paper- Thank you Madam/Sir.

Answer-But still I made slight change in the title.

Earlier, “NUSINERSEN, NEWER DRUG FOR SPINAL MUSCULAR ATROPHY”

Changed to, “NUSINERSEN, AN EXON 7 INCLUSION DRUG FOR SPINAL MUSCULAR ATROPHY: A MINIREVIEW”

- 2) Although the description of the characteristics, especially of the basic research results of nusinersen is not very detailed, it is scientifically correct.

Answer-Another reference[9] added .

- 3) “the lack of a description of other registered drugs for treating SMA makes the paper one sided. In order to appreciate the significance of nusinersen for the clinical practice, at least the clinical results of the gene therapy Zolgensma and the newly registered risdiplam (Evrysdi) should be mentioned.”

Answer-Done Madam/Sir. All the newer therapies and trials are briefly added to the manuscript alongwith their references.

- 4) “The authors only mention that the drug is registered by FDA. Nusinersen has broad international marketing authorization in many countries. The very high price of nusinersen are above the accepted pharmacoeconomic limits in many countries, not only in the US.”

Answer- Rightly said Madam/Sir. It has been accepted in Europe,Australia, Newzealand,Canada.Same has been added to the text.

- 5) “Finally I suggest that when presenting data on different motor functions comparing point values on specific scales, it would be very helpful if the authors would shortly describe what do these functional scale differences represent in actual motor function for the patients”.

Answer-Done